Jun 7, 2022

Drug combination shows promise against cancer’s ‘death star’ protein

Posted by in categories: biotech/medical, genetics

A drug combination targeting multiple mutant versions of cancer’s “death star” protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.

The two– was effective against with a range of mutations to the KRAS gene—dubbed the “death star” because its protein drives one in four cancers and has a largely impenetrable, drug-resistant surface.

The phase I trial tested the drugs VS-6766 and everolimus in 30 patients with a range of mutations to KRAS—including 11 with highly advanced, .

Leave a reply